Braving new worlds: to conquer, to endure.

Dr Moffat has had a tremendous impact on the physical therapy profession as a visionary, leader, a distinguished educator, and an accomplished clinician, administrator, and researcher. She has served as editor of Physical Therapy and, as an elected member of APTA's House of Delegates, has been instrumental in providing direction for the future of the profession. She has served as a member of innumerable committees, task forces, and boards of directors at every level within the Association. to 1991, she was elected President of APTA for the first of 2 consecutive terms.

As President, Dr Moffat spearheaded the development of the Association's Guide to Physical Therapist Practice, and she later served as a project editor of the Guide's second edition and was heavily involved in the development of the Interactive Guide on CD-ROM. Dr Moffat has worked tirelessly since 1977, when she first spoke about the professional doctoral degree for physical therapists, to lead the profession through a process of redefining the role of the physical therapist for the future and ensuring that the highest level of practice would be achieved as a requisite for assuming the title "Doctor of Physical Therapy."

As a delegate to the World Confederation for Physical Therapy, Dr Moffat has provided leadership to the international community of physical therapists. She served as APTA's voting delegate to the WCPT General Meeting, on the Executive Committee of the WCPT as the North America/Caribbean Region representative, and as a member of the Task Force on the International Definition of Physical Therapy. Dr Moffat has given more than 800 professional presentations worldwide and has taught and consulted in Taiwan, Thailand, Burma, Puerto Rico, Vietnam, Hong Kong, and Wuhan in China. For her demonstrated worldwide leadership in physical therapy, she was honored with WCPT's Mildred Elson Award for International Leadership in Physical Therapy.

Dr Moffat has been the recipient of many APTA honors and awards. She has been recognized with APTA's Lucy Blair Service Award and as a Catherine Worthingham Fellow. She has received 2 diversity, awards from the Advisory' Panel on Minority Affairs, the R Charles Harker Policy Maker Award from APTA's Health Policy amt Administration Section, and the Robert Dicus Outstanding Service Award from APTA's Private Practice Section. The most significant acknowledgments of her lifelong commitment to service are the New York Chapter's Dr Marilyn Moffat Distinguished Service Award and APTA's newly created Marilyn Moffat Leadership Award.

To be selected as the 35th recipient of the Mary McMillan Lecture Award is a most humbling experience, as I join the ranks of some of the most respected and honored members, both past and present, of our profession. I began my physical therapy career the year the first McMillan Lecture Award was given and am in the wonderful position of having personally known every one of nay 34 predecessors: Mildred Elson, who served as an inspiration for much of nay involvement in the international aspects of physical therapist practice; Catherine Worthingham, whose major study on physical therapy education I had the honor of publishing when I was editor of our Journal; Ruby Decker; Emma Vogel; Helen Kaiser; Margaret Rood, whose McMillan Lecture many of us will never forget; Lucy Blair, with whom l worked at the national office; Maggie Knott; Lucille Daniels; Helen Hislop, with whom I had many hours of, let's say, "bantering" in the early days concerning a professional doctoral degree for physical therapists, which I supported from as early as 1977; Jane Carlin, to whom I had the pleasure of personally bringing the Catherine Worthingham Fellow Award; Mary Clyde Singleton, with whom I worked closely when I was editor of Physical Therapy; Margaret Moore, who was such a strong figure in physical therapy education in my early days; Helen Blood; Florence Kendall, who continues to be a larger-than-life role model for all of us even at the age of 94 years; Sue Hirt; Dottie Voss, who with Maggie Knott and others paved the way for approaching movement from a different perspective; Nancy Watts, with whom I shared time at many educational conferences; Eugene Michels--Mike--who challenged all of us to validate what we do; Geanie Johnson, who has been a professional and personal counselor for many years; Dot Pinkston, who I got to know, not only as a physical therapist, hut also as a cook, during my first editorial hoard meeting in a 3-bedroom house in Laguna Beach; Charles Magistro, who has been a friend and confidant for many years and who even put up with my miniskirts at national office; Ruth Wood, whose sense of humor and good nature I have so appreciated, especially when she had to put up with me as a roommate at an international meeting; Don Lehmkuhl, another friend and pioneer in recognizing the importance of research in our profession; Bob Bartlett, who, of this entire group, is the physical therapist who I have known the longest--we were both graduates of New York University, both at Rusk Institute, both New York Chapter Presidents, and both APTA Presidents--a lifelong professional friend and mentor; Marylou Barnes, who is another individual with the best sense of humor and who dedicated so much of herself to the profession; Gary Soderberg, with whom I spent 11 hours literally glued to his hip in a station wagon as 6 of us attempted to get from an APTA Committee on Physical Therapy Education Meeting in Washington to Nashville, Tennessee, in the worst snowstorm DC had ever seen--a great friend and supporter; Bella J May, who showed me that you could attend an APTA conference, work hard, and still find time to exercise; Shirley Sahrmann, with whom I shared many exciting times in the House of Delegates as we both supported diagnosis and practice without referral; Suzann Campbell; Ruth Purtilo; Jules Rothstein, who was one of my students and who has made his mark on our professional publications; Steve Wolf, who showed us that collaborative research was certainly possible and evidence-based practice a necessity; and last, but not least, Pare Duncan. Our profession owes a great debt of gratitude to each and every one of these individuals.

I have the fantastic opportunity of looking at braving new worlds, to conquer and to endure. The turn of the century and the millennium was a rare moment in time, a chance to dream about the possibilities of the future, a chance to look at how we must function in this evolving world, and a chance to look at how we must ensure the viability of our profession. We will be confronted with major changes as a result of these brave new frontiers and concomitant technological revolutions that may change or make obsolete many of the disorders with which we have historically dealt, as well as many of the traditional patterns of physical therapy service delivery that we have known.

To begin, I will highlight some of the exciting new developments. Terms that are increasingly being used, some still not in dictionaries--"stem cell biology," "tissue-engineered implants," "immunogenetics," "tissue-inductive factors," "gene-transfer technologies," "convergence of cellular and electronic research," "tissue scaffolding," and "virtual reality"--are paving the way for potential changes that were until recently considered science fiction. And then we must look to how we conquer and endure as our profession reaches toward its 90th anniversary.

Cardiovascular/Pulmonary Developments

Vascular

Let's begin with the cardiovascular and pulmonary systems. Peripheral vascular disease is treated in numerous ways by opening blocked vessels. In many cases, angioplasty can be performed without surgery. Stent grafts inserted into blood vessels bypass diseased arteries (Fig. 1).

[FIGURE 1 OMITTED]

Thrombolytic therapy uses clot-busting drugs delivered to the blockage to treat deep vein thrombosis, phlebitis, venous stasis disease, and pulmonary embolism. These drugs are frequently combined with other treatments, such as angioplasty. (1) The treatment of pulmonary embolism uses percutaneous thrombectomy, whereby a catheter to the clot uses a device to break up the clot into easily absorbed pieces. (2,3) Deep vein thrombosis is managed in several ways, including laser, (4) radio frequency energy, (5) sclerotherapy, (5) phlebectomy, (6) and endoscopic repair for cases of vascular disease with ulceration. (7)

Cardiac

Drugs used for decreasing or removing cholesterol will continue to be developed. Recently, 47 patients with atherosclerotic bean disease were given a synthetic version of high-density lipoprotein. At the end of only a 5-week clinical trial, coronary artery plaque formation was reduced by an average of 4.2%. (8,9)

Studies continue to look at those things that portend heart disease. Elevated C-reactive protein levels have been shown to be related to cardiovascular risk. (10) High levels of lipoprotein-associated phospholipase [A.sub.2] have been noted before individuals actually had coronary events. (11) Homocysteine was a promising indicator initially, but later studies have been disappointing. (12) Fibrinogen levels were thought to be predictors of heart disease, but recent data suggest that they may not be. (13)

High levels of lipoprotein(a) are generally showing a strong tie to heart disease risk. (14)

Robotic-computer-assisted heart surgery and minimally invasive heart surgery, or off-pump coronary artery bypass graft (CABG) or beating heart bypass surgery, will continue to be refined. Evidence points to reducing the risk of complications and decreasing the incidence of neurocognitive dysfunction. (15)

A National Institutes of Health (NIH) study is looking at the implantation of autologous skeletal myoblasts into myocardial scar tissue areas to enhance myocardial performance. Preliminary data indicate that the implantation also may be done at the same time as CABG surgery, leading to increased myocardial muscle performance. (16)

Stem cell research will appear repeatedly throughout this presentation. Injections of adult stem cells into damaged myocardial tissue in patients with severe congestive heart failure at the time they were undergoing off-pump cardiac bypass surgery improved cardiac function. Ejection fractions went from below 35% preoperatively to 44% to 50% at 6-month follow-up. (17)

Injecting stem cells using minimally invasive techniques in patients with inoperable congestive heart failure is being investigated. Other work will give stem cells to patients with implanted heart-assist devices who are awaiting cardiac transplant.

Some reports support the use of bone narrow stem cells to regenerate heart cells and blood vessels. Researchers (18,19) showed that transplantation of a person's own stem cells through direct intracoronary injection increased blood flow and metabolism in the myocardial cells in failing hearts and increased cardiac function.

Stem cells were used to lower pulmonary arterial hypertension in rats. The vascular progenitor cells from the rats' marrow actually engrafted into the microcirculation and formed tiny new blood vessels in the pulmonary circulatory system. (20)

On another front, researchers have found a strong relationship between the severity of heart disease and the level of circulating endothelial progenitor cells. They feel that it might soon be possible to prevent atherosclerosis by injecting progenitor cells into patients and that the possibility exists of retraining a patient's own stem cells to differentiate into progenitor cells that can repair damaged arteries. (21)

Pulmonary

Transplantation of human adult stem cells in damaged lung tissue results in spontaneous regeneration of lung cells. The concept that circulating stem cells are actually going into organ tissue and repairing damage has far-reaching implications for the treatment of many lung diseases, such as emphysema and cystic fibrosis. (22)

Progress continues in attempting to treat the gene abnormality that causes cystic fibrosis. (23) The effectiveness of an investigational gene-transfer aerosolized agent is being investigated in individuals with mild to moderate cystic fibrosis because earlier results displayed a positive trend in lung function. (24) Others are looking at a unique form of gene therapy using compacted DNA with the hope of producing a protein to correct the basic defect in cystic fibrosis. (25)

Stroke

The initial management of stroke is aimed at treating the "brain attack" and intervening with urgency to reduce morbidity and mortality. Treatment is directed at dissolving blood clots, opening narrowed carotid arteries, treating ruptured blood vessels in the brain, and determining what is occurring at a cellular level.

Dissolving clots is done in the period immediately following a stroke. Tissue plasminogen activator (tPA) is administered within the first 3 hours of the stroke to break up or reduce the size of clots. (26,27)

When therapy cannot be initiated within 3 hours or when treatment with tPA is not sufficient, intra-arterial thrombolysis may be used. Tissue plasminogen activator or other clot-busting drugs, such as prourokinase, are delivered directly to the site of the clot. In the largest ongoing clinical trial, 40% of patients treated with prourokinase reported excellent recovery after 90 days compared with only 25% of patients who did not get the treatment. In addition, clogged arteries were successfully opened in 66% of patients treated with intra-arterial thrombolysis compared with 18% who were not. (28) If a stroke is the result of atherosclerotic narrowing of the carotid arteries, follow-up angioplasty and stenting may be needed to open the blocked artery and prevent another stroke. (29)

Treatment of ruptured vessels is done using embolization, in which a clotting agent is delivered to the hemorrhagic area. This technique is used for patients at high risk for brain surgery or when the location of the rupture makes surgery difficult. The technique can be used to treat aneurysms and arteriovenous malformations before they rupture. (30)

Treatment of stroke is increasingly being looked at from the cellular level. Mechanisms of neurotoxicity due to particular amino acids are being investigated. Many new drugs, especially the neurotransmitters, have the potential to reduce the damage and mediate its effects. Studies also are being conducted on how glial cells die, and these results will undoubtedly open new possibilities for treatment. Animals that received a protein called E-selection on a regular schedule had almost no strokes compared with those that did not receive it. (31)

From a therapeutic standpoint, alternatives are under study. Technology has led to the development of robotic stroke therapy that augments physical therapy (Fig. 2). Robotic devices ultimately may result in substantial improvements in the speed and quality of recovery. Robotic systems can assist or resist elbow and shoulder motions in three-dimensional (3-D) space and have a bimanual mode to enable users to practice mirror imaging of upper-extremity exercises. Preliminary results have shown improvements in the level and speed of recovery of functional performance of individuals with hemiplegic upper-extremity impairments. (32-35)

[FIGURE 2 OMITTED]

The use of a mechanized gait trainer for 4 weeks with physical therapy for subjects with hemiparesis who were chronic wheelchair users resulted in improvement of gait ability in all subjects. (36) Velocity, cadence, and stride length improved. The kinesiologic electromyogram of selected lower-limb muscles revealed a more physiologic pattern]m Researchers are currently looking at robotic-assisted gait training with all exoskeletal system for facilitating the recovery of stable walking patterns in patients who have had a stroke (Fig. 3). (37)

[FIGURE 3 OMITTED]

Constraint-induced, movement-based therapy has been shown to improve motor function and the use of the upper extremity in individuals with hemiparesis, even after chronic stroke (Fig. 4). Overcoming learned nonuse and inducing use-dependent cortical reorganization appear to be responsible for this improvement. Currently, research is under way to design instrumentation to enable patients to do the program at home. (38-41)

[FIGURE 4 OMITTED]

Studies now being funded are looking into whether combining exercises with anesthesia that blocks both motor and sensory function may improve hand movements, (42) whether administration of amphetamines with rehabilitation speeds motor recovery after a stroke, (43) and whether the use of transcranial magnetic stimulation or transcranial direct current stimulation coupled with exercise enhances performance of patients with chronic stroke. (44,45)

Diabetes

Stem cell use also is under consideration in the management of diabetes. Insulin-producing cells for transplantation can be generated from adult pancreatic stem cells. (46)

Technological advances for administration of insulin will be in the areas of implantable pumps, transdermal applications, and inhaled or oral spray insulin. New drugs will emerge aimed at both diabetes and obesity. The roles of exercise and diet will continue to be important.

Musculoskeletal Developments

The World Health Organization, working with the Bone and Joint Decade, hopes to help nations prepare for the increasing numbers of individuals with musculoskeletal disabilities. (47) Innovative tissue-engineering tools will alter the treatment of many musculoskeletal disorders. Cell destiny may be tantalizingly manipulated. The use of stein cells, microprocessors, advanced computer integration, tissue-inductive factors, new biomaterials, and gene-transfer technologies will break new ground.

Amputations

The management of patients with amputations has undergone revolutionary changes. These changes have included the use of space-age materials such as silicones, titanium, and carbon fiber, state-of-the-art technology in computer-aided design and computer-aided manufacture (Fig. 5), finite element analysis using computational methodologies to determine when a prosthesis is tight enough to be stable without causing tissue damage, and myoelectric circuitry.

[FIGURE 5 OMITTED]

Spring-loaded shock absorbers make participation in sports such as rock climbing realistic. (48) Innovative intersection of the human body and prosthetic technology enables sprinting and long-distance running (Fig. 6). (49) There is no doubt that the prosthetic limbs of tomorrow will mimic human limbs in ways we never thought possible.

[FIGURE 6 OMITTED]

Microprocessors in prosthetic knee joints control the swing of the prosthesis. They can recognize when the wearer is losing balance and automatically adjust the knee to prevent a fall (Fig. 7). These "intelligent" prosthetic devices, along with miniaturization, new power sources, and more complex computer control systems, will enable the user to concentrate on normal activities without limitations. (50)

[FIGURE 7 OMITTED]

Advanced lower-extremity prostheses have myoelectric control with transducers on the bottom of the foot that send electrical signals to the residual limb, which picks up the signals and transmits them to the brain, just like a natural foot. The brain then knows the pressure on different parts of the sole. (51,52)

Research is under way on the use of myoelectric signals to control dexterous robotic and prosthetic hands (Fig. 8). This research may eventually lead to comfortable, lightweight, and relatively inexpensive prosthetic hands acting in a nearly lifelike manner in response to the myoelectric signatures of as many as 6 different grips.

[FIGURE 8 OMITTED]

Cylindrical, precision, hook, and lateral grasping modes are currently available. (53-55) In the future, prosthetic limbs will allow more sense of feel to both the hands and feet, and they will even be able to detect soft, rough, cold, and hot.

Work has been under way with direct attachment of prosthetic limbs into the residual bone, similar to tooth implants, called osseointegration. (Fig. 9). The need for weight bearing through prosthetic sockets is eliminated. Thus, we are seeing the convergence of cellular and electronic research and an era of prosthetics that will be part person and part machine. (56-58)

[FIGURE 9 OMITTED]

A fascinating phenomenon related to limb amputation is the scientific investigation of animals that are able to regenerate amputated limbs. Although most have been invertebrates, a newt, which is a type of salamander and a vertebrate, is able to regenerate a limb in approximately 3 weeks after amputation. Being able to grow new tissue and organs has incredible implications for people with amputations. (59)

Fractures

Fracture healing is a major concern for physical therapists. Demineralized bone matrix, a sterile tissue gel, has been harvested from donor bones. It is mixed with pulverized allograft and delivered to the fracture site to provide the osteoinduction or scaffolding upon which osteogenesis can occur. (60)

A nanotechnology invention of injectable calcium phosphate-based biomaterial--that is, a "flowable" bone cement--is capable of stabilizing a fractured bone within 5 to 15 minutes. Because of its superior compressive strength, it can be used for both weight-bearing and non-weight-bearing bones. This new material will potentially be used for vertebroplasties to stabilize osteoporotic spinal fractures, eliminating the current side effects found using polymethyl methacrylate. (61)

Studies suggest that early treatment of spinal fractures with vertebroplasty can strengthen the spine, prevent further fractures, and improve posture. (62) Technological approaches to vertebroplasty (Fig. 10) include the use of new materials that will convert to bone and stimulate bone growth. Vertebroplasty also may be used preventively in the future to treat fragile vertebra. Researchers hope that "kyphoplasty," involving injecting biomaterial into a small balloon in a collapsed vertebra, will restore or prevent height loss. (62)

[FIGURE 10 OMITTED]

Although these techniques have been applied to vertebral fractures, the future management of all fractures may be achieved by gluing them together, rather than through the use of multiple types of hardware from plates to screws and joint replacement.

Cartilage, Tendon, and Meniscal Repair

Technological advances in the area of cartilage, tendon, and meniscal repair include the work on a new class of bioabsorbable polymers for practical implant materials. Cartilage regeneration is being investigated, as is seeding of chondrocytes into a synthetic matrix that can be molded into a cartilage defect. The cartilage would be grown in vitro, implanted into the body to be absorbed, and replaced with hyaline-like cartilage. (63,64)

Recombinant versions of human collagen have been produced for bone and cartilage repair. More than 20 different types of collagen have been identified within the human genome, opening up new possibilities for tissue scaffolding. (65)

Patch grafts of porcine small intestine are being used for meniscal repair and regeneration. The graft allows ingrowth of human cells, acts as a scaffold, and will have its use in thin, weakened tissues, for example, with chronic, old quadriceps femoris muscle ruptures and rotator cuff tears. (64)

A tissue-engineering strategy, using mechanical and biological approaches, has been developed to repair ruptured anterior cruciate ligaments by engineering new ligament strands--as seen against the quarter (Fig. 11). The ligament is custom-engineered from a patient's or donor's adult bone marrow stem cells. (66)

[FIGURE 11 OMITTED]

Chains of amino acids, or peptides, are being used with collagen scaffolding to treat injured cartilage from a cellular level. Viscoelastic products from polymers and hyaluronic acid products are being studied for their roles in protecting, healing, and repairing cartilage and soft tissues. Research has shown that bone morphogenetic proteins linked to a collagen carrier induce new tendon/ligament formation. (67,68)

The use of mesenchymal stem cells for healing cartilaginous, osseous, and tendon defects has been studied for more than 10 years. (69) Stem cells have been experimentally used to create cartilaginous tissue for repair and regeneration. So far, the stem cells have been implanted in meniscus defects in rabbits with good success. (70) Experimentation has been done to evaluate the potential of mesenchymal stem cells in the treatment of osteogenesis imperfecta. (71)

Intervertebral Disks

Artificial intervertebral disks have been implanted for several years in Europe and Asia as an alternative to fusion, preserving spinal motion and perhaps delaying degenerative changes in surrounding spinal segments (Fig. 12). Data from experimental clinical trials in the United States are indicating shorter operative times and earlier return to work. (72)

[FIGURE 12 OMITTED]

Tissue engineering may advance the treatment of intervertebral disks. The possibility exists that implantation of cell-gels or the use of bone morphogenic proteins may restore intervertebral disks. Bone morphogenic proteins also are being used to produce a spinal fusion. (73) Gene therapy may well be the next avenue of investigation for spinal fusion. (74)

Osteoarthritis 

Arthritis currently affects nearly 1 of every 6 people, and it is estimated that, by 2020, almost 1 in 5 people will be affected. The management of osteoarthritis is affected by technological advances. Autologous cartilage transplantation via arthroscopic surgery is a possible treatment for traumatic articular" cartilage defects. (75,76)

Investigators are searching for genes that appear to be related to certain forms of inherited arthritis and that would lead to new treatment. Researchers also feel that osteoarthritis is well suited to local gene therapy, whereby genes are introduced intra-articularly into the synovium and cartilage. This gene therapy may lead to blocking joint damage and promoting repair. (77)

The use of glucosamine and chondroitin sulfate supplements continues to undergo investigation. A 3-year international study of 212 patients showed that patients taking glucosamine felt 20% better and that the knee joints were spaced almost as evenly as when the study began. (78)

A meta-analysis to assess the efficacy of glucosamine and chrondroitin on knee osteoarthritis revealed that glucosamine improved .joint space narrowing and both supplements reduced pain and stiffness and improved physical functioning and joint mobility. (79) In 2000, the NIH awarded a $6.6 million grant to direct a 4-year clinical trial investigating the effects of glucosamine and chondroitin on 1,600 patients. (80)

A tissue-engineering biotechnology company is hoping to enable stem cell technology, to grow cartilage from skin. The company's initial goal is to be able to cure the majority of arthritic joints. According to a company spokesperson, "Dermal fibroblasts can easily be acquired directly from the patient's skin and can easily be multiplied prior" to conversion into cartilage forming cells." (81)

Another interesting avenue of research has been with sea cucumbers, which have no internal skeleton but do have a connective tissue that is dense and fibrous and can change back and forth from flexible to stiff (Fig. 13). Using this connective tissue for repairing a torn Achilles tendon would simply be done by using this substance as an ointment to form new bonds between the collagen fibrils at the site of the tear--no gap, no scar, and no loss of strength. (82)

[FIGURE 13 OMITTED]

Osteoporosis

Hibernating black bears are being studied because they do not undergo bone density loss during their 3 to 5 months of hibernation. Researchers (83) are investigating calcitonin and parathyroid hormones in bears and humans that may lead to new therapies.

Researchers have succeeded at inducing early (pre-fat) cells to become fully developed bone cells. (84) In all of us, cells in the bone marrow must decide whether to become a bone cell or a fat cell. As people age, the number of cells available to make this decision decreases, and most of those cells become lat cells, a contributing factor for osteoporosis. This approach could have important implications in promoting bone regeneration. (84)

Genetic engineering, a combination of gene therapy and tissue engineering, is reported to result in the delivery of genetically modified stem cells and is thought to eventually provide new avenues of treatment for osteoporosis. (85) However, with mice studies failing to show major osteoblastic activity in situations of estrogen deficiency, an osteoinductive carrier or some other cell-inducing agent with the mesenchymal stem cells may need to be added to achieve significant bone regeneration. (86) Investigation also is under way to determine the ability of adult stem cells to restore normal bone physiology. (87)

Neuromuscular Developments

Technology will affect the physical therapist management of patients with neuromuscular dysfunction. Mapping of the brain has given us greater insight into this central mechanism R)r human performance (Fig. 14). Electroencephalographic analyses revealing the inter dependence of brain areas shed new light on our ever-growing body of knowledge concerning brain function (Fig. 15). Functional magnetic resonance imaging in real time reveals which portions of the brain are activated and when (Fig. 16).

[FIGURE 14-16 OMITTED]

Multiple Sclerosis

The immune system protein known as "osteopontin" was noted in 2001 to be a critical factor in the immune attack of multiple sclerosis and its progression. (88) Currently, work is on the development of a DNA vaccine to tone down osteopontin. (89)

High levels of genes that had previously been found only in bones, allergic responses, and pregnancy were found in patients with multiple sclerosis. Among the genes that were overexpressed in multiple sclerosis were a histamine receptor and proteins associated with pregnancy. These results could lead to the regular use of antihistamines to treat these patients. (90) Statins, the cholesterol-lowering drugs, also have been used in the treatment of multiple sclerosis and have reduced the size and number of brain lesions. (91)

Researchers have identified molecules that underlie nerve fiber degeneration in patients with secondary progressive multiple sclerosis. In autopsy studies, they found a strong link between nerve damage and the presence of 2 molecules, a sodium channel and a sodium-calcium exchanger. These findings may lead to new therapies. (92) Investigation also is under way in the treatment of patients with multiple sclerosis using autologous stem cell transplantation. (93)

Research will determine the role of genetic risk factors and their modification and the role of environmental triggering factors, such as viruses or toxins in multiple sclerosis. Identification of factors involved in the immune attack in the brain and spinal cord, such as cellular and subcellular targets and the T cells, is needed.

Muscular Dystrophy

Scientists may soon be able to influence muscle formation in patients with muscular dystrophy because they have found that enzyme inhibitors can switch the pathway of muscle precursor cells or myoblasts from simply reproducing themselves to becoming mature cells that form muscle fibers or myotubules. (94) Further research will be directed at discovering whether the cells induced to form muscle will restore muscle function when transplanted into a mouse model. (94) The finding that limb-girdle muscular dystrophy, type 2B, is caused by a genetic deficiency of the protein dysferlin may ultimately lead to the first effective treatments. (95)

Experimenters continue to evaluate the potential of mesenchymal stem cells in the treatment of Duchenne muscular dystrophy. They have managed to use stem ceils to strengthen the muscles of mice with a form of muscular dystrophy. (96) Researchers are hoping to combine the power of stem ceils and gene therapy to develop a treatment to combat muscular dystrophy. (97)

Parkinson Disease

Innovative treatments for Parkinson disease include the use of genetics, deep brain stimulation, new drugs, surgical ablation, and cell implantation. Familial genetic mutations have been found in Parkinson disease, and encoding proteins, such as parkin, are creating new genetic ways to define the disease. (98) However, the role of genetic factors that have been established in early-onset forms of familiar parkinsonism is not clear in late-onset Parkinson disease. (99) Gene-by-gene interactions are important in Parkinson disease susceptibility. (100) Inhibition of the subthalamic nucleus via deep brain stimulation suppresses the symptoms in animal models of Parkinson disease, and high-frequency chronic stimulation does the same in humans. (101)

Neurotrophic proteins appear to protect nerve cells from the early death that prompts Parkinson disease. Patients who received a neurotrophic factor directly into the putamen had improved motor performance while they were off medication, improved functioning in activities of daily living, and reduced medication-induced dyskinesia. (102)

Neuroprotective agents, such as naturally occurring enzymes that appear to deactivate "free radicals," may be linked to the damage done to the nerve cells in Parkinson disease. Neuroprotective drags that block biochemical pathways leading to cell death are under investigation. (103)

Researchers have studied the implant of fetal pig neural tissues into the brain to restore the degenerated area. In clinical trials, a reduction in symptoms was observed in younger patients implanted with the pig tissues. (104,105)

The genetic code of individual cells has been modified to create dopamine-producing cells from other cells, including those from the skin. (106) Mouse stein cells transformed into neurons transplanted into a rat model were shown to form functional connections and reduce disease symptoms. (107) The use of selected stem cells continues to he investigated in Parkinson disease. (108-110)

Cerebral Palsy

Brain repair through the use of stem cells for the treatment of cerebral palsy is an area forging fascinating research activities (Fig. 17). Precursor neural cells grown in the lab generate mature neurons and glial cells. After the transplantation into the brains of young mice, the neural precursor cells give rise to functioning neurons and astrocytes, a star-shaped cell of the brain and spinal cord. Researchers have shown in mice that mature stem cells from the bone marrow will migrate to the site of brain injury. Further investigation will attempt to see if putting additional stem cells in the circulatory system of mice with ischemic brain injury can augment the repair of brain tissue. (111) In addition, work will look at the particular types of stem cell (eg, hematopoietic or marrow stromal cells) to see if one is more effective than the other. (112)

[FIGURE 17 OMITTED]

Research has shown that bleeding in the brain unleashes dangerously high amounts of glutamate. Although glutamate is normally used in the brain for communication, too much overstimulates the brain's cells and causes destruction. Scientists are now looking closely at glutamate to detect how its release harms brain tissue and spreads the damage. (113)

Investigators are attempting to ascertain if certain drugs may prevent neonatal stroke. Some of these promising drugs appear to reduce the excess production of dangerous chemicals in the brain and may help control brain blood flow and volume. (113)

Scientists are working to develop new drugs--and new ways of using existing drugs--to help relieve the symptoms of cerebral palsy. The use of implanted pumps that deliver a constant supply of antispasticity drugs into the fluid around the spinal cord is being explored, in the hope of improving effectiveness and reducing side effects. (113)

Training devices (eg, stationary bicycles and treadmills linked to sensory stimulation) for providing input into the brain also are increasingly supported modes of enhancing function in individuals with cerebral palsy. The Lite Gait system (Fig. 18, left) * and the WalkAble (Fig. 18, right) * are 2 such units oil the market. (114) The SMART Walker (Fig. 19) ([dagger]) was developed to enable children with cerebral palsy to stand, ambulate with hands-free support, and explore their environment. (115) The use of constraint induced movement therapy for children with hemiparesis has been shown to result in acquisition of more new motor skills, increased amount and quality of movement of the affected arm at home, and increased unprompted use of the affected upper extremity, all of which were maintained for over 6 months (Fig. 20). (116)

[FIGURE 18-20 OMITTED]

Spinal Cord Injury and Other Paralytic Disorders

One reads the stories of the remarkable activity that Christopher Reeve (Fig. 21) has exhibited. His ability to voluntarily move body parts and feel 9 years after his spinal cord injury must make us all rethink those things we learned in school about spinal cord injuries. Intensive physical therapy utilizing functional electrical stimulation, water therapy, harnessed weight bearing, breathing exercises, and cardiovascular/aerobic training has resulted in movement activities not thought possible. As early as 2002, rats have been given neuronal stem cells after extensive spinal cord resection and have shown some functional recovery. (117) As these factors are investigated carefully, other technological advances also will help individuals with spinal cord and other paralytic disorders.

[FIGURE 21 OMITTED]

Long leg orthoses are currently available that lock the knee when needed during stance and unlock it during swing. The use of tubular stainless steel allows for the development of very lightweight, but extremely strong, orthotic devices. (118)

Neuroprostheses were surgically implanted in a group of volunteers who have paraplegia with long-standing paralysis (Fig. 22). The neuroprothesis enabled standing, transfers, release of a hand from a support device for object manipulation, and performance of a swing-to gait with a walker. (119)

[FIGURE 22 OMITTED]

The next generation of technology in the use of implantable neuroprosthetic systems for upper-extremity function will be based on the earlier work of the Freehand system, ([double dagger]) which is no longer produced. (120-122) The new systems hopefully will allow filler hand control, active extension of the elbow, or improved sensory feedback strategies. Study has shown that the addition of a triceps muscle electrode to the neuroprosthetic hand grasps can increase arm extension and controllable workspace. (123)

Since 1999, the use of cortical signals to control neuroprosthetic devices for patients with paralysis has been investigated. A miniaturized neuroprosthesis is under development that will be suitable for implantation into the brain. This type of device will potentially eliminate all external signal and power wiring devices now needed for neuroprostheses. (124-126)

Research is under way involving advances made in detecting neural signals and translating them into command signals to control devices. Tiny probes were implanted into several brain regions of 2 rhesus monkeys. Each monkey learned to move a joystick that controlled a cursor on a computer screen. To get a drink of juice, the monkey had to move the cursor to a ball target when it appeared on the screen (Fig. 23, left). Electrical patterns from the monkey's brain were collected as it performed the tasks. When the monkey was skilled at the task, the joystick was disconnected. Initially, the monkey jiggled the stick and just stared at the screen. Even though the joystick was not working, the monkey's reaching and grasping motor plans were being sent to a computer, which translated those signals into movements on screen. Suddenly, the monkey realized that it could guide the cursor and grasp an object on the screen just by thinking it (Fig. 23, right). The monkey's arm dropped, and the muscles no longer contracted. We see the monkey's ability to move a robot arm with thoughts, thus bringing tire merger of mind and machine one step closer, and a potentially major innovative approach to management of patients with spinal cord lesions or paralysis from other causes. (127,128)

[FIGURE 23 OMITTED]

Exoskeleton Technology

Research has demonstrated that the spinal cord may be able to learn to initiate steps without input from the brain through a new therapy called "locomotor training." Robomedica is testing a robotic step-training device for retraining individuals with neurologic impairments to walk (Fig. 24). Tim device will monitor and record patient progress and demonstrate measurable results. (129)

[FIGURE 24 OMITTED]

Exoskeleton technology, has endless possibilities for many patients with paralysis, especially of the lower extremities. The RoboKnee ([section]) is being tested as a motorized brace. Sensors in the shoe and along the leg detect the pressure being exerted by the leg onto the ground and detect muscle movement. Requiring only partial movement of the legs, the RoboKnee can do up to 80% of the work of the legs while walking and climbing. Thus, for patients who had poliomyelitis or those who have muscular dystrophy, this type of device may be invaluable. (130)

An exoskeleton for elderly people also has been developed. The Hybrid Assistive Leg ([parallel]) is a robotic suit with joint-angle sensors, myoelectric sensors, and floor sensors that enable elderly people or those with physical disabilities to walk at a speed of 4 km/h with little physical effort, climb stairs, and sit and stand (Fig. 25). Everything is built into a backpack. Faint muscle signals must at this stage be present. The eventual aim is to make a suit that is thin enough to be worn like underwear and allow the user to run and freely move the tipper extremities. (131)

[FIGURE 25 OMITTED]

Wheelchair Technology

Seating systems are increasingly adapted through computerized technology. Computer analysis of peak pressures during sitting and the times at which they occur facilitate the correct seat to prevent skin breakdown (Fig. 26). (132)

[FIGURE 26 OMITTED]

Wheelchair technology is progressing. The Computer-Controlled Power Wheelchair Navigation System (#) remembers paths that have been laid out for it. The wheelchair is initially maneuvered through the patient's operational environments, and all of the destinations are programmed into the computer. An ultrasound profile is assigned so that the patient can approach solid objects (eg, the edge of the user's desk) as required on the computer pathway to get from point A to point B. The patient selects the desired destination from a menu with a chin switch, voice, eyelids, or pointer, and the chair proceeds to that location (Fig. 27). (133-135)

[FIGURE 27 OMITTED]

Wheelchairs will navigate previously inaccessible places. The iBOT ** is a wheelchair that is capable of going into four-wheel drive, going over stones, going over logs, climbing stairs, elevating, and balancing on 2 wheels (Fig. 28). (136)

[FIGURE 28 OMITTED]

The Human Genome Project

The Human Genome Project (HGP) was an international research effort to sequence and map all of the Homo sapiens genes--together known as the genome (Fig. 29). The project gave us the chance to read nature's complete genetic blueprint for building a human being. The ultimate quest is to understand the role it plays in health to be better able to diagnose, treat, and prevent disease. One of the latest projects is to develop a new kind of map of the human genome to hasten the discovery of the variant genes thought to underlie common diseases such as diabetes, asthma, and cancer. (137)

[FIGURE 29 OMITTED]

Technological Developments in Physical Therapy

Physical Therapist Examination

Physical therapist examination will witness many changes in the sophistication and the reliability and validity of data obtained with the instruments used for tests and measurements. Three-dimensional gait analysis (Fig. 30, left) and biomechanical studies (Fig. 30, right) are vital for quantifying an individual's performance. (138,139) The use of moving platforms is one way that a patient's balance control can be assessed. Stimuli are given through the platform and through virtual reality, situations (Fig. 31). (140) The use of optical motion capture for gait analysis has helped speed diagnosis and treatment for patients with cerebral palsy (Fig. 32). (141)

[FIGURES 30-32 OMITTED]

Force scan (F-scan) units (Fig. 33) provide increasing data about gait parameters. (142) Fiber optic sensors will generate data on the range of motion of body parts as seen in an analysis of finger flexion. (143) Gloves will sense joint angles (Fig 34). (144) For examination of range of motion, wounds, muscle bulk, and chest expansion, the FastSCAN, ([dagger][dagger]) a 3-D handheld laser scanner, now with a stylus option, instantly provides an exact replica of the scanned object on the computer screen (Fig. 35). (145)

[FIGURES 33-35 OMITTED]

Virtual Reality

In physical therapy, virtual reality systems will increasingly augment intervention programs. (146) A handimmersive workstation generates a virtual environment suitable for training dexterous manipulation (Fig. 36). (147) Patients are motivated by seeing themselves engaging in various sports and games, which may improve focus and adherence. (148) Virtual reality may be used for examining and providing interventions for vestibular disorders (149) and may be used for patients with other movement disorders, strokes, Parkinson disease, and spinal cord injuries.

SnowWorld ([double dagger][double dagger]) was developed for pain control to allow patients with extensive burns to simulate flying through an icy canyon and shooting snowballs to help put out the fire, thus diverting their attention away from treatment procedures and suppressing reliving the burn experience (Fig. 37). (150,151) For patients with hemiplegia with involved side neglect, several rehabilitation approaches are possible, including optokinetic stimulation, eye-patching, and vestibular stimulation through head-mounted displays. (152-156) Virtual reality is a way to teach the patient with a cerebrovascular accident and spatial neglect, or the patient with Parkinson disease, to safely cross a busy street (Fig. 38). (157)

To Conquer, to Endure

These past few years have been truly awesome as we look at what has been and think about what is to come. Technology, which had its great early thrust during the space era, has provided more opportunities, more excitement, and more potential for physical therapist practice. Changes in disease entities, changes in the recovery potential for patients thought to have irreversible lesions, and changes in therapeutic interventions will all have an impact on physical therapist practice. What happens if many of the patients for whom we have provided services are no longer in need of our services? Are we poised for the sorts of revolutionary changes that occurred in our practice when Salk discovered the polio vaccine and when the 2 great wars were over?

I have no doubt that we will be. However, we must be sure that the world recognizes us as experts capable of examining and providing physical therapy intervention for the vast variety of patients and clients we see.

Although we have in our armamentarium of skills many tools that enable us to provide services for our patients and clients, there are none more important than exercise. It is the intervention that is truly supported by thousands of studies over the years, so evidence-based practice is not a question in this arena.

Therapeutic exercise provided by physical therapists is the intervention that will enable our increasingly elderly populations to keep themselves fit and avoid the heartaches of prolonged institutional care. It is the intervention that should preclude our middle-aged populations from getting themselves into trouble when they think about starting a later-in-life exercise program. It is the intervention that should enable our school-age populations to begin weight training in the correct and physiologically sound way. It is the intervention that puts our patients oil the road to recovery and to enhanced function in self-care, home management, and work, community, and leisure activities and tasks. It is the intervention that can be provided in health-based facilities, in residential care facilities, in the community, and in the home. Our Guide to Physical Therapist Practice (158) recognized the importance of therapeutic exercise by placing it first in the hierarchy of interventions that physical therapists use in practice. And every single practice pattern has exercise as an intervention.

And yet I would challenge you by asking how many of us are truly experts in exercise and how much of the world recognizes us as experts in exercise in all of its ramifications. Our profession began in 1917 and 1918 with exercise as its primary, mode of intervention. Reconstruction aides for the most part came from educational backgrounds in gymnasia, with strong exercise knowledge and skills, and for nearly 50 years that remained true of our academicians and practitioners. When the baccalaureate degree became the minimum for professional [entry-level] practice, we lost that strong exercise base. Now it is time to reassert our capabilities in this arena, for if we do not, there are many others who are increasingly offering exercise programs without physical therapist training, Recent educational offerings for fitness instructors included "Strength Training for Wheelchair Users," "Circuit Resistance Training for Persons With Spinal Cord Injuries," "Postpartum Recovery Techniques and Exercises," "Exercise aim Diabetes," "Fibromyalgia: the Exercise Connection," "How to Work With Chronic Postural Imbalances and Structural Difficulties," "Spine Instability--How Do We Recognize It and What Can We Do?" "A Step-by-Step Approach to Training Clients With Neuromuscular Disorders," and "Post-Rehabilitation Strategies for Working With Low Back, Knee, or Shoulder Pain," to name just a few of the numerous offerings via courses, educational sessions, and videotapes.

The following questions are put to you, the practitioner, and to our faculty and students involved in our physical therapist education programs. How many of us can do an aerobic capacity/endurance test for individuals without impairments using treadmill, ergometer, steps, and walk/run protocols, and how many can do a test with a 12-lead electrocardiograph? How many of us have the educational base in all facets of exercise--from passive, active, resistive, and plyometric exercises, to every type of free-weight and weight-training machine exercise, to every conceivable exercise using elastic bands and tubes, stability balls, medicine balls, BOSU, ([section][section]) BAPTS ([parallel][parallel]) rollers, slide boards, trampolines, pulleys, and body blades, to the vast array of aquatic exercises with and without equipment, to the hundreds of exercises that may be used to increase flexibility, to all of the exercises for enhancing aerobic conditioning, breathing, posture, balance, coordination, agility, and relaxation?

How many of us know the principles, the value, the role, and the application of periodization for conditioning? How many of us know all of the principles and the exercises or postures incorporated in Pilates, yoga, and tai chi, to name a few of the complementary exercise techniques, or in aerobic or step classes? How many of us know all the requirements of designing and setting up a fitness center as part of a physical therapist practice, including considerations of access, flooring, environmental factors, electrical considerations, mirrors, arrangement of equipment, cleaning, risk management, and liability?

How many of us could sit for and pass the American College of Sports Medicine Exercise Specialist examination that tests knowledge and skills in a variety of exercise assessment, training, rehabilitation, risk factor identification, and lifestyle management services to individuals with or at risk for cardiovascular, pulmonary, and metabolic diseases? Or the Certified Strength Conditioning Specialist examination that tests in-depth knowledge of: (1) exercise science; (2) the principles of test selection and administration and the specific tests used for assessing maximum muscular strength, anaerobic power, anaerobic capacity, muscle endurance, aerobic capacity, agility, speed, flexibility, body composition, and anthropometry; (3) exercise techniques; and (4) organization and administration of a conditioning facility? I know of only 2 physical therapist education programs in the entire country that require the latter examination to be taken by their students.

I would venture to say that our education programs have often lost sight of what is necessary to truly make us exercise experts. We bad the rare opportunity as we transitioned to professional doctoral programs to completely redesign our curricula and not just add on pharmacology and radiology and perhaps some differential diagnosis to existing programs. In that process, we all should have looked long and hard at those skills that will ensure the viability of our practice, those that will establish us as exercise experts regardless of what technology does to the populations that we have served.

The development of researchers is not the aim of professional physical therapist education; the aim is to develop good consumers of research. The development of primary care practitioners who are able to treat acute infections, do family planning, provide childhood immunizations, and perform annual physical examinations is not the aim of professional education; the aim is to develop first-contact physical therapist practitioners. The development of practitioners who have minimal levels of skill in physical therapist examinations and interventions is not the aim of professional education; the aim is to develop experts.

And so the time is propitious for us to rightfully assume our role as those professionals who are best able to design appropriate exercise programs for individuals across the age span. But to do that will rake a concerted effort by each of us. APTA's Section on Geriatrics has made a start in this arena. It has established a task force based on the belief that we should be experts in movement and exercise, with a thorough knowledge of pathology and its effects on all systems. We should be the ideal professionals to promote, guide, and manage the exercise activities and efforts of America's older adults. And so the Section on Geriatrics aims to see that physical therapists have the skills and the knowledge base and are indeed recognized as exercise experts for the aging population.

The North American-Caribbean Region of the World Confederation for Physical Therapy also recently established a new goal of ensuring that physical therapists are or will become exercise experts for the aging population, with the intent of developing a position statement for the 2007 General Meeting to hopefully be adopted by all member organizations. I believe that APTA, too, must now champion the cause by integrating such capability and recognition as experts into its strategic planning, its educational offerings, its public relations programs, and its involvement with government and regulatory agencies. With such a major thrust, physical therapists will once again assume their position of leadership as exercise experts for our population.

Conclusion

This millennium is a time of great excitement for health care--and for physical therapy. Our challenge as physical therapists is to ensure that, whoever our patients or clients may be (and I am certain that there will always be new patients with new diagnoses and new clients with new health promotion needs), those in need of our services receive them at the highest level of expertise of which we are capable. We physical therapists are so very capable of imagining new solutions, creating new hope for our patients and clients, and, more than braving them, conquering our new worlds.

I look forward to working with you, my friends and colleagues, to that end. Thank you from the bottom of my heart for this wonderful honor.

References

(1) Girolami B, Bernardi E, Prins MH, et al. Antiplatelet therapy and other interventions after revascularization procedures in patients with peripheral arterial disease; a meta analysis. Eur J Vasc Surg. 2000;19: 370-380.

(2) Fava M, Loyola S, Huete I. Massive pulmonary embolism: treatment with the hydrolyser thrombectomy catheter. J Vasc Interv Radiol. 2000; 11:1159-1164.

(3) Reckers JA, Baarslag HJ, Koolen MG, et al. Mechanical thrombetctomy for early treatment of massive pulmonary embolism. Cardiovasc Interv Radiol. 2003;26:246-250.

(4) Kaudewitz P, Klovekorn W, Rother W. Treatment of leg vein telangiectases: 1-year results with a new 940 nm diode laser. Dermatol Surg. 2002;28:1031-1024.

(5) Weiss RA. Radiofrequency-mediated endovenous occlusion. In: Weiss RA, Feied CF, Weiss MA, eds. Vein Diagnosis and Treatment: A Comprehensive Approach. New York, NY: McGraw-Hill Inc; 2001:211-221

(6) Zotto LM. Treating varicose veins with transilluminated powered phlebectomy. AORN J. 2002;76:980-994.

(7) Bergan J, Kumin N, Owens E, Sparks S. Surgical and endovascular treatment of lower extremity venous insufficiency. J Vasc Interv Radiol. 2002;13:563-568.

(8) Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA. 2003;290: 2292-2300.

(9) Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004; 291:1071-1080.

(10) Shishehbor MH, Bhatt DL, Topol EJ. Using C-reactive protein to assess cardiovascular disease risk. Clev Clin J Med. 2003;70:634-640.

(11) Caslake MJ, Packard CJ. Lipoprotein-associated phospholipase A2 (platelet-activating factor acetylhydrolase) and cardiovascular disease. Curt Opin Lipidol. 2003;14:347-352.

(12) Braly J, Holford P. The H Factor Solution: Homocysteine, the Best Single Indicator of Whether You Are Likely to Live Long or Die Young. North Bergen NJ: Basic Health Publications Inc; 2003.

(13) Hackam DG, Anand SS. Emerging risk factors for atherosclerotic vascular disease: a critical review of the evidence. JAMA. 2003;290: 932-940.

(14) Craig WY, Neveux LM, Palomaki GE, et al. Lipoprotein(a) as a risk factor fox ischemic heart disease: meta-analysis of prospective studies. Clin Chem. 1998;44:2301-2306.

(15) Robot assisted surgery. Cleveland Clinic Heart Center Web site. Available at: http://www.clevelandclinic.org/heartcenter/pub/history/ future/robotics.asp. Accessed January 13, 2004.

(16) A phase I, open-label, non-randomized, dose escalation, multi center study to assess the safety and cardiovascular effects of autologous skeletal myoblast (MyoCell[TM]) implantation by a transendocardial catheter delivery system (MyoCath[TM]) in congestive heart failure patients post myocardial infarction(s) with previous placement of an implantable cardioverter defibrillator (ICD). Available at: http:// www.clinicaltrials.gov/ct/gui/show/NCT00054678?ordcr=14. Accessed January 15, 2004.

(17) Patel AN, Vina RF, Geffner, L, et al. Surgical treatment for congestive heart failure using autologous adult stem cell transplantation: a prospective randomized study. Paper presented at: 84th Annual Meeting of the American Association for Thoracic Surgery; Toronto, Ontario, Canada; April 25, 2004.

(18) Strauer BE, Brehm M, Zeus T, et al. Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. Circulation. 2002;106:1913-1918.

(19) Strauer BE, Brehm M, Zeus T, et al. Mending the broken heart: resident and non-resident primitive cells. Paper presented at: AHA Scientific Session; November 10, 2003; Orlando, Fla.

(20) Stewart D, Deng YZ, Zhang Q, et al. Stem cells in the treatment of pulmonary arterial hypertension in rats. Paper presented at: AHA Scientific Session; November 10, 2003; Orlando, Fla.

(21) Kunz G, Liang G, Cuculoski F, et al. Progenitor Cells Predict Heart Disease Severity. New Orleans, La: American College of Cardiology; March 9, 2004.

(22) Suratt B, Cool CD, Serls AE, et al. Human pulmonary chimerism after hematopoietic stem cell transplantation. Am J Resp Crit Care Med. 2003;16:318-322.

(23) Gene therapy: the future of cystic fibrosis treatment? Available at: http://www.healthnewsflash.com/conditions/cystic_fibrosis.htm#therapy. Accessed May 12, 2004.

(24) Gene studies: AAV-CFTR gene transfer agent. Available at: http:// www.cff.org/research/genetic_studies_aavcftr_gene_transfer_ agent.cfm. Accessed May 12, 2004.

(25) Gene therapies: CF gene therapy trial using compacted DNA? Available at: http://www.cff.org/research/gene_therapy_compacted_ DNA.cfm. Accessed May 12, 2004.

(26) Albers GW, Bates VE, Clark WM, et al. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA. 2000;283:1189-1191.

(27) Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324: 71-86.

(28) Furlan A, Higashida R, Wechsler L, et al. Intra arterial prourokinase for acute ischemic stroke: the PROACT II study--a randomized controlled trial. JAMA. 1999;282:2003-2011.

(29) Straus SE, Majumdar SR, McAlister FA. New evidence for stroke prevention: scientific review. JAMA. 2002;288:1388-1395.

(30) US Multicenter, Randomized Controlled Study Comparing the Performance of Onyx (EVOH) and TRUFILL (n-BCA) in the Presurgical Embolization of Brain Arteriovenous Malformations (BAVMs). Washington, DC: Georgetown University Hospital; 2003.

(31) Takeda H, Spatz M, Ruetzler C, et al. Induction of mucosal tolerance to E-selectin prevents ischemic and hemorrhagic stroke in spontaneously hypertensive genetically stroke-prone rats. Stroke. 2002; 33:2156-2164.

(32) Burgar CG, Lum PS, Shor PC, Machiel-VanderLoos HS. Development of robots for rehabilitation therapy: the Palo Alto VA/Stanford experience. J Rehabil Res Dev. 2000;37:663-673.

(33) Krebs HB, Volpe BT, Aisena ML, Hogan N. Increasing productivity and quality of care: robot-aided neuro-rehabilitation. J Rehabil Res Dev. 2000;37:639-652.

(34) Lum PS, Burgar CG, Shor PC, et al. Robot-assisted movement training compared with conventional therapy techniques for the rehabilitation of upper-limb motor function after stroke. Arch Phys Med Rehabil. 2002;83:952-959.

(35) Volpe BT, Ferraro M, Krebs HI, Hogan N. Robotics in the rehabilitation treatment of patients with stroke. Curt Atheroscler Pap. 2002;4: 270-276.

(36) Hesse S, Werner C, Uhlenbrock D, et al. An electromechanical gait trainer for restoration of gait in hemiparetic stroke patients: preliminary results. Neurorehabil Neural Repair. 2001;15:39-50.

(37) Hidler J, Hornby G. Gait restoration in hemiparetic stroke patients using goal-directed, robotic-assisted treadmill training. Clinical trial at National Rehabilitation Hospital, 2003. Available at: http://anbl.cua. edu/Clinical.cfm. Accessed March 1, 2004.

(38) Taub E, Wolf S. Constraint induced movement techniques to facilitate upper extremity use in stroke patients. Topics in Stroke Rehabilitation. 1997;3(4):38-61.

(39) Kunkel AB, Kopp B, Muller G, et al. Constraint-induced movement therapy for motor recovery in chronic stroke patients. Arch Phys Med Rehabil. 1999;80:624-628.

(40) Levy CE, Nichols DS, Schmalbrock PM, et al. Functional MR/ evidence of cortical reorganization in upper-limb stroke hemiplegia treated with constraint-induced movement therapy. Am J Phys Med Rehabil. 2001;80:4-12.

(41) Schaechter JD, Kraft E, Hilliard TS, et al. Motor recovery and cortical reorganization after constraint-induced movement therapy in stroke patients: a preliminary study. Neurorehabil Neural Repair. 2002; 16:326-328.

(42) National Institute of Neurological Disorders and Stroke clinical research study. Improvements of hand function in chronic stroke related to upper arm anesthesia. Available at: http://www.clinicaltrials. gov/ct/show/NCT00006414?order=11. Accessed April 26, 2004.

(43) National Institute of Neurological Disorders and Stroke clinical research study. Motor recovery in recent stroke patients treated with amphetamine and physical therapy. Available at: http://www. clinicaltrials.gov/ct/gui/c/alb/show/NCT00001783. Accessed April 26, 2004.

(44) National Institute of Neurological Disorders and Stroke clinical research study. Repetitive transcranial magnetic stimulation in chronic stroke patients: dose effect on motor cortex excitability, motor performance, and safety using different stimulation parameters. Available at: http://clinicalstudies.info.nih.gov/cgi/detail.cgi?A_03-N-0049-html. Accessed April 26, 2004.

(45) National Institute of Neurological Disorders and Stroke clinical research study. Improvement of motor learning in chronic stroke patients by transcranial dc stimulation. Available at: http:// clinicalstudies.info.nih.gov/cgi/detail.cgi?A_03-N-0267.html. Accessed April 26, 2004.

(46) Path G, Seufert J. Current status and perspectives of stem cell therapy for the treatment of diabetes mellitus. Med Klin. 2003;98: 277-282.

(47) Chronic rheumatic conditions. World Health Organization Web site. Available at: http://www.who.int/ncd/cral. Accessed April 9, 2004.

(48) Marks LJ, Michael JW. Science, medicine, and the future: artificial limbs. BMJ. 2001;323:732-735.

(49) Inside Smithsonian Research. Washington, DC: Smithsonian Office of Public Affairs; Spring 2004.

(50) C-Leg[R] System. Otto Bock HealthCare Web site. Available at: http://www.ottobockus.com/products/lower_limb_prosthetics/c-leg. asp. Accessed March 4, 2004.

(51) Sandia National Laboratories news release: agreement signed to create "smart" leg. Available at: http://www.sandia.gov/media/ NewsRel/NR2000/smartleg.htm. Accessed November 12, 2003.

(52) Smart Integrated Lower Limb (SILL). Available at: http://www. sandia.gov/isrc/SILL.html. Accessed December 12, 2003

(53) Ferguson S, Dunlop GR. Grasp recognition from myoelectric signals. Paper presented at: Proceedings of the 2002 Australasian Conference on Robotics and Automation; November 27-29, 2002; Auckland, New Zealand.

(54) Carrozza MC, Vecchi F, Sebastiani F, et al. Experimental analysis of an innovative prosthetic hand with proprioceptive sensors. Paper presented at: IEEE International Conference on Robotics and Automation ICRA; September 14-19, 2003; Taipei, Taiwan.

(55) Carrozza MC, Suppo C, Sebastiani F, et al. The spring hand: development of a self-adaptive prosthesis for restoring natural grasping. Auton Robots. 2004:16;125-141.

(56) Integrum Web site. Available at: http://www.integrum.se and http://www.alfred.org.au/departments/plastic_and_reconstructive_ surgery_unit.html. Accessed January 15, 2004.

(57) Branemark R, Branemark P-I, Rydevik B, Myers RR. Osseointegration in skeletal reconstruction and rehabilitation. J Rehabil Res Dev. 2001;38:175-181. Also available at http://www.alfred.org.au/ departments/plastic_and_reconstructive_surgery_unit.html.

(58) Mark LJ, Michael JW. Science, medicine, and the future. BMJ. 2001;323:732-735.

(59) Alvarado AS. Regeneration in the metazoans: why does it happen? BioEssays. 2000;22:578-590.

(60) Smith WR, Caton LA, Ziran BH, et al. Efficacy of composite allograft and demineralized bone matrix in the treatment of high-energy tibial plateau fractures with extensive bone loss. Poster presentation at: Orthopaedic Trauma Association Annual Meeting; October 22-24, 2000; Charlotte, NC.

(61) USCEment: synthesis of reactive calcium phosphate nanoparticles and their use in making biomimetric biomaterials for bone repair. Available at: http://ip.researeh.sc.edu/catalog/00262.htm. Accessed May 26, 2004.

(62) Vertebroplasty treatments. Society of Interventional Radiology Web site. Available at: http://www.sirweb.org/patPub/vertebroplasty Treatments.shtml. Accessed December 9, 2003.

(63) Peterson L, Brittberg M, Kiviranta I, et al. Autologous chondrocyte transplantation: biomechanics and long-term durability. Am J Sports Med. 2002;30:2-12.

(64) Kelly EB. Tissue implants: conquering the impossible. Available at: http://www.orthopedictechreview.com/issues/julaug01/pg32.htm. Accessed May 26, 2004.

(65) Spiro RC, Nokelainen M, Yang C, et al. Recombinant human collagens for bone and cartilage repair. Euro Cells Materials. 2002; 4(suppl 1):16.

(66) Homegrown ligaments could repair debilitating knee injuries. Tufts Journal (serial online). Available at: Available at: http://tuftsjournal. tufts.edu/archive/2002/march/briefs/ligament.shtml. Accessed May 26, 2004.

(67) Bobic V. Tissue repair techniques of the future: options for articular cartilage injury. Report presented at: Techvest, LLC First Annual Conference on Tissue Repair, Replacement and Regeneration; October 27-28, 1999; New York, NY.

(68) Available at: http://www.medscape.com/viewarticle/405599. Accessed March 4, 2004.

(69) Bruder SP, Fink DJ, Caplan AI. Mesenchymal stem cells in bone development, bone repair, and skeletal regeneration therapy. J Cell Biochem. 1994,56:283-294.

(70) Johnstone B. Mesenchymal stem cells and chondrogenesis. Euro Cells Materials. 2002;4(suppl 1):27.

(71) Horwitz EM, Prockop DJ, Fitzpatrick LA, et al. Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med. 1999;5:309-313.

(72) Total disc replacement: ProDisc. Available at: http://www.spine-health. com/research/discupdate/artificial/artificial04.html. Accessed May 31, 2004.

(73) Johnsson R, Stromquist B, Aspenberg P. Randomised radiostereometric study comparing osteogenic protein-1 (BMP-7) and autograft bone in human noninstrumented posterolateral lumbar fusion. Spine. 2002;27:2654-2661.

(74) Degenerative disc disease. Available at: http://www.spinesource. com/BackPain-Disorders/disc-degeneration.html. Accessed May 31, 2004.

(75) Bruns J, Kahrs J, Kampen J, et al. Autologous perichondral tissue for meniscal replacement. J Bone Joint Surg Br. 1998;80:918-923.

(76) Knutsen G, Engebretsen L, Ludvigen T, et al. Autologous chondrocyte implantation compared with microfracture in the knee: a randomized clinical trial. J Bone Joint Surg Am. 2004;86:455-464.

(77) Evans CH, Gouze JN, Gouze E, et al. Osteoarthritis gene therapy. Gene Ther. 2004;11:379-389.

(78) Reginster JY, Deroisy R, Paul I, et al. Glucosamine sulfate significantly reduces progression of knee osteoarthritis over 3 years: a large, randomized, placebo-controlled, double-blind, prospective trial. Paper presented at: American College of Rheumatology Annual Meeting. November 17, 1999; Boston, Mass.

(79) Richy F, Bruyere O, Ethgen O, et al. Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: a comprehensive meta-analysis. Arch Intern Med. 2003;163:1514-1522.

(80) Glucosamine/Condroitin Arthritis Intervention Trial (GAIT) begins patient recruitment. Available at: http://nccam.nih.gov/news/ 19972000/121100/. Accessed June 5, 2004.

(81) Gentis obtains rights for skin to cartilage transformation technology. Available at: http://www.gentisinc.com/News1.htm. Accessed May 31, 2004.

(82) Simmers A. Catch and release. Natural History. 2003;11:36-37.

(83) Donahue SW, Vaughan MR, Demers LM, Donahue HJ. Bone formation is not impaired by hibernation (disuse) in black bears Ursus americanus. J Exp Biol 2003;206:4233-4239.

(84) Skillington J, Choy L, Derynck R. Bone morphogenetic protein and retinoic acid signaling cooperate to induce osteoblast differentiation of preadipocytes. J Cell Biol. 2002;159:135-146.

(85) Shea LD, Smiley E, Bonadio J, Mooney DJ. DNA delivery from polymer matrices for tissue engineering. Nat Biotechnol 1999;17: 551-554.

(86) Gasser JA. Stem cells in the treatment of osteoporosis. Eur Cells Materials. 2003;6(suppl 2):21.

(87) Cellular Replacement Therapy[TM] (CRT). Available at: http://www. primegenbiotech.com/technology.php. Accessed June 1, 2004.

(88) Chabas D, Bavanzini SE, Mitchell D, et al. The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science. 2001;294(5547):1731-1735.

(89) Steinman L. Engineering better cytokines. Nat Biotechnol 2003;21: 1293.

(90) Steinman L, Heller R. Aix array of possibilities for multiple sclerosis. Nat Med. 2002;8:451-453.

(91) Vollmer T. Cholesterol-lowering drug effective in treating most common form of MS. Scientific presentation at: American Academy of Neurology Annual Meeting; April 1, 2003; Honolulu, Hi.

(92) Craner MJ, Newcombe J, Black JA, et al. Molecular changes in neurons in multiple sclerosis: altered axonal expression of Nav1.2 and Nav1.6 sodium channels and [Na.sup.+]Ca[2.sup.+] exchanger. Proc Natl Acad Sci U S A. 2004;101:8168-8173.

(93) Carreras E, Saiz A, Marin P, et al. CD[34.sup.+] selected autologous peripheral blood stem cell transplantation for multiple sclerosis: report of toxicity and treatment results at one year of follow-up in 15 patients. Haematologica. 2003;88:306-314.

(94) Iezzi S, Cossu G, Nervi C, et al. Stage-specific modulation of skeletal myogenesis by inhibitors of nuclear deacetylases. Proc Natl Acad Sci U S A. 2002;99:7757-7762.

(95) Recent research developments supported by the Muscular Dystrophy Association. Available at: http://www.mdausa.org/publications/ resdev.html. Accessed June 1, 2004.

(96) Gussoni E, Soneoka Y, Strickland CD, et al. Dystrophin expression in the mdx mouse restored by stem cell transplantation. Nature. 1999;401:390-394.

(97) Sampaolesi M, Torrente Y, Innocenzi A, et al. Cell therapy of alpha-sarcoglycan mill dystrophic mice through intra-arterial delivery of mesoangioblasts. Science. 2003;301(5632):487-492.

(98) Brain banking for neurodegenerative disease. Curr Opin Neurolobiol. 2003;4:459-463.

(99) Dekker MC, van Swieten JC, Houwing-Duistermaat JJ, et al. A clinical-genetic study of Parkinson's disease in a genetically isolated community. J Neurol. 2003;250:1056-1062.

(100) Pankratz N, Nichols WC, Uniacke SK, et al. Genome-wide linkage analysis and evidence of gene-by-gene interactions in a sample of 362 multiplex Parkinson disease families. Hum Mol Genet. 2003;12: 2599-2608.

(101) Benabid AL. Deep brain stimulation for Parkinson's disease. Curr Opin Neurobiol. 2003;13:696-706.

(102) Gill SS, Patel NK, Hotton GR, et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med. 2003;9:589-595.

(103) Anderson A. Research offers hope to patients with Parkinson's disease. Available at: http://www.fromthelab.net/vol01/is2/02oct_n3. htm. Accessed June 9, 2004.

(104) Henkel J. Parkinson's disease: new treatments slow onslaught of symptoms. Available at: http://www.fda.gov/fdac/features/1998/ 498_pd.html. Accessed January 17, 2004.

(105) Neuroscience clinic. Available at: http://www.pallidotomy.com/ tissue_and_cell_.html. Accessed January 17, 2004.

(106) Treatments for Parkinson's disease. Available at: http://www. holistic-online.com/Remedies/Parkinson/pd_treatments.htm. Accessed January 17, 2004.

(107) Kim JH, Auerbach JM, Rodriguez-Gomez JA, et al. Dopamine neurons derived from embryonic stem cells function in an animal model of Parkinson's disease. Nature. 2002;418(6893):50-66.

(108) Bjorklund A, Dunnett SB, Brundin P, et al. Neural transplantation for the treatment of Parkinson's disease. Lancet Neurol 2003;2: 437-445.

(109) Isacson O, Bjorklund LM, Schumacher JM, Towards full restoration of synaptic and terminal function of the dopaminergic system in Parkinson's disease by stem cells. Ann Neural 2003;53(suppl 3): S135-S146.

(110) Jiang Y, Balkrishna NJ, Reinhardt RL, et al. Pluripotency of mesenchymal stem cells derived from adult bone marrow. Nature. 2002; 418(6893):41-49.

(111) Hill WD, Hess DC, Martin-Studdard A, et al. SDF-1 (CXCL12) is upregulated in the ischemic penumbra following stroke: association with bone marrow cell homing to injury. J Neuropathol Exp Neural. 2004;63:84-96.

(112) Bartley J, Carroll JE. Stem cell therapy for cerebral palsy. Expert Opin Biol Ther. 2003;3:541-549.

(113) Cerebral palsy: hope through research. National Institute for Neurological Disorders and Stroke Web site. Available at: http:// www.ninds.nih.gov/health_and_medical/pubs/cerebral_palsyhtr.htm# What%20Specific%20Treatments. Accessed June 3, 2004.

(114) The treatment of cerebral palsy. United Cereblal Palsy Web site. Available at: http://www.ucp.org/ucp_generaldoc.cfm/1/4/11654/ 11654-11654/4790. Accessed June 5, 2004.

(115) Advanced Orthotic Designs Inc Web site. Available at: http://www. aodmobility.com/Contact_Us/Profile/body_profile.htm. Accessed April 9, 2004.

(116) Taub E, Ramey SL, DeLuca S, Echols K. Efficacy of constraint-induced movement therapy tar children with cerebral palsy with asymmetric motor impairment. Pediatrics. 2004;113:305-312.

(117) Teng YD, Lavik EB, Qu X, et al. Functional recovery following traumatic spinal cord injury mediated by a unique polymer scaffold seeded with neural stem cells. Proc Natl Acad Sci U S A. 2002;99: 3024-3029.

(118) Areas of practice: lifelong knee/ankle/foot care--major technological advances in knee-ankle-foot (KAFO's) orthoses. SCOPe Orthotits & Prosthetics Inc Web site. Available at: http://www.scop.net/ areas_kneeAnkleFoot.htm. Accessed April 14, 2004.

(119) Agarwal S, Triolo RJ, Kobetic R, et al. Long-term user perceptions of an implanted neuroprosthesis for exercise, standing, and transfers after spinal cord injury. J Rehabil Res Dev. 2003;40:241-252.

(120) Taylor P, Esnouf J, Hobby J. Pattern of use and user satisfaction of Neuro Control Freehand system. Spinal Cord. 2001;39:156-160.

(121) Johnson D, Whitworth H. Recent developments in plastic surgery. BMJ. 2002;325:319-322.

(122) Taylor P, Esnouf J, Hobby J. The functional impact of the Freehand System on tetraplegic hand function: clinical results. Spinal Cord. 2002;40:560-566.

(123) Memberg WD, Crago PE, Keith MW. Restoration of elbow extension via functional electrical stimulation in individuals with tetraplegia. J Rehabil Res Dev. 2003;40:477-486.

(124) Lauer RT, Peckham PH, Kilgore KL. EEG-based control of a hand grasp neuroprosthesis. Neural Rep. 1999;10:1-5.

(125) Lauer RT, Peckham PH, Kilgore KL, Heetderks WJ. Applications of cortical signals to neuroprosthetic control: a critical review. IEEE Trans Rehabil Eng. 2000;8:205-207.

(126) Mojarradi M, Binkley D, Blalock B, et al. A miniaturized neuroprothesis suitable for implantation into the brain. IEEE Trans Neural Sys Rehabil Eng. 2003:1:38-42.

(127) Nicolelis MA, Dimitrov D, Carmena JM, et al. Chronic, multisite, multielectrode recordings in macaque monkeys. Proc Natl Acad Sci U S A. 2003;100:11041-11046.

(128) Carmena JM, Lebedev MA, Crist RE, et al. Learning to control a brain-machine interface for reaching and grasping by primates. Public Library Sci Bio. 2003;1:193-208.

(129) Robomedica Inc Web site. Available at: http://www.robomedica. com/projects.htm. Accessed April 7, 2004.

(130) Yobotics Inc Web site. Available at: http://www.yobotics.com. Accessed April 7, 2004.

(131) Hunter D. Exoskeleton soon available for the elderly. Available at: http://www.betterhumans.com/Errors/index.aspx?aspxerrorpath=/ Exoskeleton_Soon_Available_for_the_Elderly.Article.2003-08-221.aspx. Accessed April 8, 2004.

(132) The ClinSeat[TM] System. Tekscan Web site. Available at: http:// www.tekscan.com/medical/system_clinseat.html. Accessed December 10, 2003.

(133) Fehr L, Langbein WE, Skaar SB. Adequacy of power wheelchair control interfaces for persons with severe disabilities: a clinical survey. J Rehabil Res Dev. 2000;37:353-360.

(134) Del Castillo G, Skaar SB, Fehr L. Extending teach and repeat to pivoting wheelchairs. J Systemics Cybernetics Informatics. Publication pending. Available at: http://www.iiisci.org/journal/SCI/Browser.asp?var. Accessed April 12, 2004.

(135) Del Castillo G, Skaar SB, Cardenas JA, Fehr L. An approach to sonar obstacle detection in an autonomous vision-based mobile robot. Preliminary version of report. Available at: http://www.nd.edu/ ~gdelcast/Docs.htm. Accessed April 12, 2004.

(136) A wheelchair that climbs and a new set of eyes. Available at: http://www.ergoweb.com/news/detail.cfm?id=633. Accessed May 20, 2004.

(137) Human Genome Program. Genomics and Its Impact on Science and Society: A 2003 Primer. Washington, DC, US Department of Energy; 2003.

(138) Ariel Performance Analysis System. Ariel Dynamics Inc Web site. Available at: http://www.sportsci.com/adi2001/adi/products/apas/ system/description.asp. Accessed January 20, 2004.

(139) Gait video tape. Available at: http://www.vicon.com/main/ technology/img/ws%20movie%20video:jpg. Accessed January 20, 2004.

(140) Xtreme Sports Snowboard Simulator. Available at: http://www. vrealities.com/xtreme.html. Accessed January 30, 2004.

(141) Gait analysis. Vicon Motion Systems Web site. Available at: http:// www.vicon.com/main/applications/gait_analysis.shtml. Accessed December 11, 2003.

(142) Medical pressure measurement overview. Tekscan Web site. Available at: http://www.teksean.com/medical/specs_mobile.html. Accessed January 12, 2004.

(143) 5DT Datagloves. Meta Motion Web site. Available at: http://www. metamotion.com/hardware/motion-capture-hardware-gloves-Datagloves.htm. Accessed January 12, 2004.

(144) Cybergloves[R]. Meta Motion Web site. Available at: http://www. metamotion.com/hardware/motion-capture-hardware-glove.Cybergloves. htm. Accessed January 12, 2004.

(145) FastSCAN[TM] Cobra[TM]: the fast and easy digital scanner. Polhemus Web site. Available at: http://www.polhemus.com/fastscan.htm. Accessed April 21, 2004.

(146) Proceedings of the 8th Annual Medicine Meets Virtual Reality Conference; January 27-30, 2000; Newport Beach, Calif.

(147) The Hand-ImmersiveWorkstation.Available at: http://www.simcen. org/surgery/hardware/ReachIn_Workstation.htm. Accessed February 20, 2004.

(148) IREX (Interactive Rehabilitation & Exercise System). Available at: http://www.irexonline.com. Accessed April 20, 2004.

(149) Whitney SL, Sparto PJ, Brown KE, et al. The potential use of virtual reality in vestibular rehabilitation: preliminary findings with the BNAVE. Neurol Report. 2002;26:72-78.

(150) Hoffman HG, Patterson DR, Carrougher GJ. Use of virtual reality for adjunctive treatment of adult burn pain during physical therapy: a controlled study. Clin J Pain. 2000;16:244-250.

(151) Human Interface Technology Lab Web site. Available at: http:// www.hitl.washington.edu/projects/burn. Accessed April 13, 2004.

(152) Pizzamiglio L, Fasotti L, Jehkonen M, et al. The use of optokinetic stimulation in rehabilitation of the hemineglect disorder. Cortex. 2004;40:441-450.

(153) Zeloni G, Fame A, Baccini M. Viewing less to see better. J Neurol Neurosurg Psychol. 2002;73:195-198.

(154) Pierce SR, Buxbaum LJ. Treatments of unilateral neglect: a review. Arch Phys Med Rehabil. 2002;83:256-268.

(155) Parton A, Malhotra P, Husain M. Hemispatial neglect. J Neurol Neurosurg Psychol. 2004;75:13-21.

(156) Weiss PL, Naveh Y, Katz N. Design and testing of a virtual environment to train CVA patients with unilateral spatial neglect to cross a street safely. Occup Ther Int. 2003;10:39-55.

(157) Boian RF, Burdea GC, Deutsch JE, Winter SH. Street crossing using a virtual environment simulator. To appear in the Proceedings of IWVR 2004, Lausanne, Switzerland. Available at: http://www.caip. rutgers.edu/vrlab/publications/papers/2004_iwvr_boian.pdf. Accessed May 14, 2004.

(158) Guide to Physical Therapist Practice. 2nd ed rev. Alexandria, Va: American Physical Therapy Association; 2003.

* Products, Education, and Rehabilitaion Solutions, PO Box 3141, Tempe, AZ 85280.

([dagger]) Advanced Orthotic Designd, Inc, 3995 Sladeview Crescent, Unit #4, Mississauga, Ontario, Canda L5L 5Y1.

([double dagger]) NeuroControl Corp, 8333 Rockside Rd, Cleveland, OH 44125.

([section]) Yobotics Inc, 1776 Mentor Ave, Suite 75-205, Cincinnati, OH 45212.

([parallel]) CYBERDYNE Inc, Graduate School of Science and Engineering, University of Tsukuba, Tsukuba, Japan (http://www.cyberdyne:jp).

(#) Vision, Dexterity and Control Laboratory, University of Notre Dame, Notre Dame, IN 46556.

** Independence Technology LLC, 45 Technology Dr, Warren, NJ 07059-5148.

([dagger][dagger]) Polhemus Inc, 40 Hercules Dr, PO Box 560, Colchester, VT 05446.

([double dagger][double dagger]) University of Washington HITLab, Seattle, WA 98195.

([section][section]) Team BOSU, 1400 Raff Rd, Canton, OH 44750.

([parallel][parallel]) Camp Healthcare, 2010 E High St, Jackson, MI 49203.

[Moffat M. Thirty-Fifth Mary McMillan Lecture: Braving new worlds: to conquer, to endure. Phys Ther. 2004;84:1056-1086.]

M Moffat, PT, PhD, FAPTA, CSCS, is Professor of Physical Therapy, New York University, New York, NY. She also is director of the Professional Doctoral Program and the Master's Program in Pathokinesiology and is in private practice. Address all correspondence to Dr Moffat at Physical Therapy Department, New York University, 380 Second Ave, 4th Floor, New York, NY 10610 (USA) ([e-mail]).

The Thirty-Fifth Mary McMillan Lecture was presented at PT 2004: The Annual Conference and Exposition of the American Physical Therapy Association; June 30, 2004; Chicago, Ill.

Photograph of Earth courtesy of NASA [c] 1968 (http://nssdc.gsfc.nasa.gov).